Roderick Wong - 18 Jun 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Jul 2025, 16:05:40 UTC
Prior SEC filing
20 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Martin Wilson, as attorney-in-fact for Roderick Wong

Key filing fact

Roderick Wong filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 18 Jul 2025.

Key facts

  • This page summarizes Roderick Wong's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Jul 2025, 16:05.

Change

  • Previous filing in this sequence was filed on 20 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001493280 Primary reporting owner

WONG RODERICK

Relationship
Director, 10%+ Owner
Address
C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature
/s/ Martin Wilson, as attorney-in-fact for Roderick Wong
Signature date
18 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value
$0
Shares
+30,000
Change %
Price
$0.000000
Shares after
30,000
Date
18 Jun 2025
Ownership
Direct
Footnotes
F1
RCKT transaction

Common Stock

Award

Transaction value
$0
Shares
+17,667
Change %
+59%
Price
$0.000000
Shares after
47,667
Date
18 Jun 2025
Ownership
Direct
Footnotes
F2
RCKT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
18,188,457
Date
18 Jun 2025
Ownership
See footnote
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.

Footnote F2

Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026.

Footnote F3

Represents shares held by certain investment funds managed by RTW Investments, LP (the "Adviser"). The Reporting Person serves as the Managing Partner and Chief Investment Officer of the Adviser and is a director of the Issuer and Chairman of the Issuer's Board of Directors.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .